SEARCH

SEARCH BY CITATION

Keywords:

  • malaria;
  • intermittent preventive treatment;
  • sulfadoxine–pyrimethamine;
  • pregnancy;
  • birth weight;
  • Democratic Republic of Congo
  • paludisme;
  • malaria;
  • traitement préventif intermittent;
  • sulfadoxine-pyriméthamine;
  • grossesse;
  • poids à la naissance;
  • République Démocratique du Congo
  • malaria;
  • tratamiento preventivo intermitente;
  • sulfadoxina pirimetamina;
  • embarazo;
  • peso al nacer;
  • República Democrática del Congo

Abstract

  1. Top of page
  2. Abstract
  3. Introduction
  4. Methods
  5. Results
  6. Discussion
  7. Acknowledgements
  8. References

Objective  To assess the effect of intermittent preventive treatment with sulfadoxine–pyrimethamine (IPTp-SP) on birth weight in sites with varying degrees of drug resistance.

Methods  Birth weight data from three regions in Democratic Republic of Congo with varying degrees of sulfadoxine–pyrimethamine (SP) resistance (1.6% in Mikalayi, 21.7% in Kisangani and 60.6% in Rutshuru) were analysed retrospectively by means of a logistic model that included the number of SP doses taken by the mother and other potentials confounding factors.

Results  The IPTp-SP reduced the risk of low birth weight (LBW) in Kisangani (adjusted OR, 0.15; IC95%, 0.05–0.46) and in Mikalayi (adjusted OR, 0.12; IC95%, 0.01–0.89). In both sites, the average birth weight was higher for mothers having received two rather than one or no SP doses (P < 0.001). In Rutshuru, IPTp-SP had an effect in primigravidae but not in multigravidae. However, after adjustment for other LBW risk factors, there was no difference in the proportion of LBW (adjusted OR 0.92; IC95%, 0.37–2.25) between women having taken at least 2 SP doses and those with only one dose or none.

Conclusion  IPT-SP remains an effective strategy in Kisangani and Mikalayi where the therapeutic failure to SP in children with clinical malaria was 21.7% and 1.6%, respectively, while IPTp-SP effect seems lower in Rutshuru where the therapeutic failure to SP was 60.6%. The threshold value of SP resistance at which IPTp-SP fails to have a significant impact on birth weight and LBW is unknown. Considering that no alternative is currently available, additional studies on the efficacy of IPTp-SP in the areas of high SP resistance such as Rutshuru are needed so that the threshold at which this intervention fails to provide any benefit is determined with some precision.

Objectif:  Evaluer l’effet du traitement préventif intermittent par le sulfadoxine-pyriméthamine (TPI-SP) sur le poids de naissance dans des sites avec des degrés différents de résistance aux médicaments.

Méthodes:  Les données des poids de naissance de trois régions de la RDC avec des degrés différents de résistance au sulfadoxine-pyriméthamine (SP) (1.6%à Mikalayi, 21.7%à Kisangani et 60.6% dans le Rutshuru) ont été analysées rétrospectivement au moyen d’un modèle logistique qui tenait compte du nombre de doses de SP prises par la mère et d’autres facteurs confusionnels potentiels.

Résultats:  Le TPI-SP réduit le risque de faible poids de naissance à Kisangani (OR ajusté: 0.15; IC95%: 0.05 à 0.46) et à Mikalayi (OR ajusté: 0.12; IC95%: 0.01 à 0.89). Dans les deux sites, le poids de naissance moyen était plus élevé pour les mères ayant reçu deux plutôt qu’une seule ou aucune dose de SP (P < 0.001). A Rutshuru, le TPI-SP a eu un effet chez les primipares, mais pas chez les multipares. Toutefois, après ajustement pour les autres facteurs de risque pour le faible poids de naissance, il n’y avait aucune différence dans la proportion des cas de faible poids de naissance (OR ajusté: 0.92; IC95%: 0.37 à 2.25) entre les femmes ayant pris au moins 2 doses de SP et celles ayant pris une seule dose ou aucune dose.

Conclusion:  Le TPI-SP demeure une stratégie efficace à Kisangani et à Mikalayi où l’échec thérapeutique au SP chez les enfants atteints de paludisme clinique était de 21.7% et 1.6% respectivement, alors que l’effet du TPI-SP semble plus faible à Rutshuru où les échecs thérapeutiques au SP étaient de 60.6 %. La valeur seuil de résistance à la SP pour laquelle le TPI-SP ne parvient pas à avoir un impact significatif sur le poids de naissance et le faible poids de naissance est inconnue. Considérant qu’aucune alternative n’est actuellement disponible, des études supplémentaires sur l’efficacité du TPI-SP dans les zones de haute résistance au SP telles qu’à Rutshuru, sont nécessaires pour que le seuil à partir duquel cette intervention ne parvient pas à fournir un bénéfice soit déterminé avec une certaine précision.

Objetivo:  Evaluar el efecto del tratamiento preventivo intermitente con sulfadoxina pirimetamina (IPTp-SP) sobre el peso al nacer en lugares con grados variables de resistencia al medicamento.

Métodos:  Se analizaron de forma retrospectiva datos del peso al nacer de tres regiones de la RDC con diferentes grados de resistencia a la sulfadoxina pirimetamina (SP) (1.6% en Mikalayi, 21.7% en Kisangani y 60.6% en Rutshuru), utilizando un modelo logístico que incluía el número de dosis de SP tomadas por la madre y otros factores de confusión potenciales.

Resultados:  El IPTp-SP redujo el riesgo de un bajo peso al nacer (BPN) en Kisangani (OR ajustado, 0.15; IC95%, 0.05–0.46) y en Mikalayi (OR ajustado, 0.12; IC95%, 0.01–0.89). En ambos emplazamientos, el peso promedio al nacer era mayor para madres que recibieron dos en vez de una o ninguna dosis de SP (P < 0.001). En Rutshuru, el IPTp-SP tenía un efecto en primigrávidas, pero no en multigrávidas. Sin embargo, después de ajustar para otros factores de riesgo de BPN, no había diferencias en la proporción de BPN (OR ajustado 0.92; IC95%, 0.37–2.25) entre las mujeres que habían tomado al menos 2 dosis de SP y aquellas con solo una dosis o con ninguna.

Conclusión:  El IPT-SP continúa siendo una estrategia efectiva en Kisangani y Mikalayi, en donde el fallo terapéutico del SP en niños con malaria clínica era del 21.7% y el 1.6%, respectivamente, mientras que el efecto del IPTp-SP parece ser menor en Rutshuru, en donde el fallo terapéutico del SP era del 60.6%. Se desconoce cual es el valor del umbral de la resistencia del SP en el cual el IPTp-SP deja de tener un impacto significativo sobre el peso al nacer y el BPN. Considerando el hecho de que actualmente no hay ninguna alternativa disponible, se requieren estudios adicionales sobre la eficacia del IPTp-SP en áreas con una alta resistencia al SP, como es el caso de Rutshuru, con el fin de determinar con precisión el umbral en el cual la intervención deja de proveer beneficios.


Introduction

  1. Top of page
  2. Abstract
  3. Introduction
  4. Methods
  5. Results
  6. Discussion
  7. Acknowledgements
  8. References

Pregnant women are highly vulnerable to malaria infection (Brabin 1983; Greenwood et al. 2005; WHO 2006; Rogerson et al. 2007; Menendez et al. 2008; Lagerberg 2008). Among the 50 millions at risk each year in endemic countries, more than half live in sub-Saharan Africa (Steketee et al. 2001; Desai et al. 2007; Menéndez et al. 2007). Malaria causes maternal anaemia and low birth weight (LBW), the latter caused by placental malaria that compromises the maternal – foetal exchanges (Steketee et al. 2001; Steketee 2003; WHO 2004, 2008a,b; Mutabingwa et al. 2005). It is estimated that maternal malaria causes more than 35% of preventable LBW, an important risk factor for infant mortality (McCormick 1985; Newman et al. 2003; Steketee 2003; Van Geertruyden et al. 2004; Sirima et al. 2006).

Intermittent preventive treatment during pregnancy with sulfadoxine–pyrimethamine (IPTp-SP) and insecticide-treated bed net (ITN) can reduce maternal anaemia and LBW by about 40% (WHO 2005a,b). Unfortunately, IPTp-SP coverage in Africa, and more specifically in the Democratic Republic of Congo (DRC), is still low, that is between 5% and 18% (WHO and UNICEF 2003; Ministère du Plan et Macro International 2008; WHO 2008a,b).

While countries are trying to increase IPTp-SP coverage, Plasmodium falciparum (Pf) has become increasingly resistant to sulfadoxine–pyrimethamine (SP) (White 2005; Briand et al. 2007; Vallely et al. 2007). In DRC, SP treatment failure by day 28 varied between 2% and 60%, which prompted the change of the first-line treatment from SP to an Artemisinin-based combination therapies, that is amodiaquine-artesunate, in March 2005 (Odio 2005).

In highly malaria endemic areas, data on SP treatment efficacy are usually collected in symptomatic children under 5 years but the results obtained are not necessarily applicable to IPTp-SP; indeed, this intervention can be reasonably effective even in areas where SP efficacy in children has declined to 50% (WHO 2008a,b). Nevertheless, it is important to continue collecting information on IPTp-SP in regions where resistance to SP is moderate to high (ter Kuile et al. 2007). We collected retrospective data on birth weight and IPTp-SP in three sites in DRC where SP efficacy was either high (in two sites) or low (one site).

Methods

  1. Top of page
  2. Abstract
  3. Introduction
  4. Methods
  5. Results
  6. Discussion
  7. Acknowledgements
  8. References

The study was carried out in three maternity clinics in areas where information on SP efficacy in 6- to 59-month-old children was available. The in vivo tests were conducted between 2002 and 2004 in Mikalayi in the south–west of the country, within 33 km of the city of Kananga; in Umoja, in the suburbs of Kisangani; and in Kiwandja, about 70 km from Goma in the Rutshuru health district (Odio 2005) (Figure 1). SP treatment failure at day 28 post-treatment was low in Mikalayi (1.6%), moderate in Kisangani (21.7%) and high in Rutshuru (60.6%) (Figure 1). These estimations are similar to those produced by other studies conducted in the same areas (Kazadi et al. 2003; Alker et al. 2008).

image

Figure 1.  Results of in vivo efficacy assessment of sulfadoxine–pyrimethamine in symptomatic malaria carried out on 6–59 months children (proportion of adequate clinical and parasitological response at day 28) (Odio 2005).

Download figure to PowerPoint

All women (i) who gave birth in 2007 in the study maternity clinics (ii) attended the antenatal care (ANC) at least once during pregnancy and (iii) whose ANC card was available for analysis were included in this study. Each maternity unit kept the ANC cards for all pregnant women from their catchment area. Hospital records and ANC cards were fully reviewed and the information transcribed. The primary outcome was the birth weight analysed both as a continuous or categorical (LBW: <2500 g) variable. Newborns were weighed by a standard procedure in the three maternity using mechanical baby scales with a precision of 10 g. The tendency of rounding the birth weight probably occurred in all three sites and should not significantly affect the results. Women were categorised according to the number of IPTp-SP doses received, into either two or more doses vs. one or none.

Mothers’ demographic and anthropometric variables were also collected, that is age, weight, height and the body mass index (BMI) as well as the number of visits to the ANC and previous pregnancy outcomes. The estimated gestational age of the newborn, estimated by last menstrual period, was obtained but not included in the analysis.

The descriptive analysis used proportions for categorical variables, means with standard deviation or median with interquartile range for continuous variables. Contingency tables were analysed using the chi-square test. Means were compared by t-test or one-way anova followed by multiple comparisons (Bonferroni). When data were not normally distributed, the Kruskal–Wallis test was used for the median.

An analysis of birth weight as well as of LBW by the number of SP doses taken by the mothers, stratified by site and gravidity range was done. OR’s homogeneity was tested by the Breslow and Day (1994) test. A logistic regression model of LBW including the number of SP doses, main outcome studied, and other potential confounding factors (parity, BMI, gestational age and number of ANC visits) selected by backward method was constructed. Interactions between site and number of SP doses were introduced into the model and tested with the likelihood ratio test. The Hosmer and Lesmeshow (2000) test was used to improve model goodness of fit. All statistical analyses were performed using STATA/IC 10.0 for Windows (StataCorp LP).

This study was approved by the authorities of the national, provincial and local Ministry of Health. The protocol was approved by the ethics commission and deontology of the Provincial Council of the Medical Board of the Oriental Province.

Results

  1. Top of page
  2. Abstract
  3. Introduction
  4. Methods
  5. Results
  6. Discussion
  7. Acknowledgements
  8. References

In total, 1393 women who had delivered in the three health facilities in 2007 were included in the study: 138 in Kisangani, 582 in Mikalayi and 673 in Rutshuru. Women in Kisangani were significantly younger than in the other two sites, though after Bonferroni correction, the difference remained significant only between Kisangani and Mikalayi (Table 1). In Kisangani the BMI, the parity and the number of living children were significantly lower than in the other two sites, while the proportion of women under 18, primigravidae and low BMI was higher. Mean birth weight was lower in primigravidae; the proportion of LBW was higher in mothers who had taken just one SP dose or none (Table 2).

Table 1.   Demographic and anthropometric characteristics of women by health facility
CharacteristicsAllRutshuruMikalayiKisanganiP
  1. *One-way anova, **Pearson’s χ2, ***Kruskal–Wallis test.

Age (year) n1367666563138 
 Mean (DS)26.0 (6.7)25.8 (6.5)26.7 (7.0)24.5 (6.9)0.002*
  <18 freq (%)93 (6.8)39 (5.9)34 (6.1)20 (14.5)0.005**
  18–39 freq (%)1220 (89.2)602 (90.4)504 (89.5)114 (82.6)
  >39 freq (%)54 (4.0)25 (3.7)25 (4.4)4 (2.9)
Gravidity n1390671582137 
 Median (P75–P25)3 (5–1)3 (5–1)3 (5–1)2 (3–0)<0.001***
  0 freq (%)250 (18.0)110 (16.4)100 (17.2)40 (29.2)<0.001*
  1–5 freq (%)892 (64.2)442 (65.9)361 (62.0)89 (65.0)
  >5 freq (%)248 (17.8)119 (17.7)121 (20.8)8 (5.8)
Living Infant n1371670564137 
 Median (P75–P25)2 (4–1)2 (4–1)2 (4–1)2 (3–0)0.006**
Height (Cm) n1019441446132 
 Mean (DS)156.6 (7.6)156.9 (6.4)154.9 (7.5)161.8 (9.0)<0.001*
  <150 freq (%)129 (12.7)48 (10.9)76 (17.0)5 (3.8)<0.001*
  ≥150 freq (%)890 (87.3)393 (89.1)370 (83.0)127 (96.2)
Weight (kg) n1061468461132 
 Mean (±DS)58.1 (7.3)59.2 (7.9)57.0 (6.7)57.7 (6.5)<0.001*
BMI (kg/m2) n873319423131 
 Mean (DS)23.7 (2.9)24.2 (2.7)23.8 (2.9)22.1 (2.4)<0.001*
  <21 freq (%)115 (13.2)31 (9.7)52 (12.3)32 (24.4)<0.001*
  ≥21 freq (%)758 (86.8)288 (90.3)371 (87.7)99 (75.6)
Number of ANC n1286673486127 
 Median (P75–P25)3 (4–2)3 (3–2)4 (4–3)3 (3–2)<0.001***
  ≥4 freq (%)415 (32.3)86 (12.8)304 (62.5)25 (19.7)<0.001*
  3 freq (%)484 (37.6)294 (43.7)140 (28.8)50 (39.4)
  2 freq (%)315 (24.5)240 (35.6)32 (6.6)43 (33.8)
  1 freq (%)72 (5.6)53 (7.9)10 (2.1)9 (7.1)
Table 2.   Birth weight and low birth weight (LBW) frequencies by health facility, gravidity and sulfadoxine–pyrimethamine (SP) doses taken by mothers
 nBirth weight (g)LBW
Mean (SD)PFreq (%)P
  1. *One-way anova, **Pearson’s χ2, ***t-test.

All13813078.3 (509.0) 126 (9.1) 
Sites
 Rutshuru6703027.0 (443.7)<0.001*55 (8.2)0.012**
 Mikalayi5743183.1 (536.4)49 (8.5)
 Kisangani1372889.8 (594.7)22 (16.1)
Gravidity
 Primigravidae2472861.5 (482.7)<0.001***38 (15.4)<0.001**
 Multigravidae11313125.8 (503.1)88 (7.8)
SP doses
 ≤1 SP dose5903070.2 (547.8)0.938*67 (11.4)0.004**
 ≥2 SP doses6943072.3 (448.2)47 (6.8)

Among the women included in the study, the percentage of those having received two IPTp-SP doses was relatively high in Rutshuru (73.7%, 496/673) and Kisangani (63.5%, 87/137), while it was extremely low in Mikalayi (23.8% 115/484) (P < 0.001). When analysing the mean birth weight by the number of IPTp-SP doses taken, no difference could be found in Rutshuru, while in the other two sites, there was a statistically significant difference between babies born to mothers having taken the two doses as compared to one or none, the latter having the lowest birth weight (Table 3). Similarly, both in Mikalayi and Kisangani, the risk of LBW was significantly lower in women having taken two IPTp-SP doses (Mikalayi: OR = 0.17; IC95%, 0.02–0.67-, P = 0.006 and Kisangani: OR = 0.16; IC95%, 0.05–0.48, P ≤ 0.001), while there was no difference in Rutshuru. This was confirmed after adjusting for other risk factors for LBW, for example first pregnancy and low BMI, which were also associated with LBW, in some sites significantly (Table 4). However, after stratification by gravidity, even in Rutshuru, the mean birth weight was higher (2833.8 g vs. 2520.7, P = 0.010) and the risk of LBW lower (OR = 0.26; IC95%, 0.07–1.19) for primigravidae who received at least two SP doses compared with those who received only one or none (Table 3), while after adjustment for other risk factors for LBW the difference did not remained statistically significant (Table 4).

Table 3.   Newborn’s weight by number of IPTp-SP doses stratified by gravidity by each site
Doses of sulfadoxine–pyrimethamine (SP)AllPrimigravidaeMultigravidae
nMean(DS)PnMean(DS)PnMean(DS)P
  1. *t-test, **Pearson’s χ2, ***Fisher’s exact test.

Birth weight (g)
 All12843071.3(496.3)0.938*2332853.5489.60.027*10483119.9485.40.918*
  ≤15903070.2(547.8) 832758.0576.6 5063121.5443.9
  ≥26943072.3(448.2) 1502906.3427.1 5423118.4526.7
 Rutshuru6703027.0(443.7)0.714*1092790.7440.50.010*5593073.1430.40.667*
  ≤11773037.5(492.0) 152520.7499.1 1623085.4464.5
  ≥24933023.3(425.5) 942833.8417.3 3973068.1416.2
 Mikalayi4773185.7(510.5)<0.001*842986.3(515.6)0.024*3933228.3499.90.002*
  ≤13633141.5(515.5) 562896.9(522.0) 3073186.1502.5
  ≥21143326.3(469.4) 283165.0(460.9) 863378.8462.7
 Kisangani1372889.8(594.7)<0.001*402745.8(512.0)0.005*962948.6621.50.001*
  ≤1502667.8(753.4) 122406.7(699.2) 372743.5769.2
  ≥2873017.4(436.6) 282891.1(326.3) 593077.3470.9
Doses of SPn%ORPn%ORPn%ORP
Low birth weight (<2500 g)
 All12848.88 0.004**23315.9 <0.001**10487.4 0.106**
  ≤159011.361 8327.71 5068.71
  ≥26946.770.57 (0.38–0.85) 1509.30.27(0.12–00.59) 5426.10.68(0.41–1.12)
 Rutshuru6708.21 0.639**10914.7 0.044***5596.7 0.912**
  ≤11779.041 1533.31 1626.81
  ≥24937.910.86 (0.48–1.70) 9411.70.26(0.07–1.19) 3977.11.04(0.49–2.38)
 Mikalayi4777.76 0.006**8414.3 0.054***3936.1 0.025**
  ≤13639.641 5619.61 3077.81
  ≥21141.750.17 (0.02–0.67) 283.60.15(0.00–1.17) 861.20.14(0.00–0.88)
 Kisangani13716.06 <0.001**4022.5 0.001***9613.5 0.014**
  ≤15032.001 1258.31 3724.31
  ≥2876.900.16 (0.05–0.48) 287.10.05(0.00–0.43) 596.80.22(0.05–0.91)
Table 4.   Risk factors for low birth weight (LBW) after adjustment
Risk factorsMikalayi (n = 342)Kisangani (n = 122)Rutshuru (n = 318)
OR (IC95%)P*OR (IC95%)P*OR (IC95%)P*
  1. Not included in the model before stratification because not significant: Number of ANC, Maternal age *Wald χ2, **No LBW infant recorded in this strata.

Number of sulfadoxine–pyrimethamine doses
 ≤110.03810.00110.853
 ≥20.12 (0.01–0.89) 0.15 (0.05–0.46) 0.92 (0.37–2.25) 
Gravidity
 03.64 (1.27–10.38)0.0161.68 (0.55–5.10)0.3622.39 (0.91–6.28)0.077
 1–51 1 1 
 >51.13 (0.29–4.45)0.857** 2.45 (0.87–6.95)0.091
BMI (kg/m2)
 <212.30 (0.68–7.76)0.1801.19 (0.38–3.79)0.7645.87 (2.29–15.06)0.001
 ≥211 1 1 

Discussion

  1. Top of page
  2. Abstract
  3. Introduction
  4. Methods
  5. Results
  6. Discussion
  7. Acknowledgements
  8. References

When analysing the mean birth weight or the risk of LBW in women who attended ANC and delivered in the three health facilities, it appears that two doses of SP had a significant impact in two sites, while in the remaining site, the impact was found only in primigravidae. Nevertheless, in this site, the difference did not reach statistical significance after adjustment for other known LBW risk factors. It is tempting to ascribe this to an attenuation of effect of IPTp-SP in Rutshuru because of the high SP resistance reported a few years earlier (Odio 2005; Alker et al. 2008). LBW or rather its risk in primigravidae compared with multigravidae has already been proposed as an indicator for monitoring the malaria burden and the effectiveness of control interventions in this highly vulnerable group (Brabin et al. 1999). The observed reduction of the risk in LBW and the increase in the mean birth weight associated with two IPTp-SP doses is comparable with those reported from other sub-Saharan African countries (Newman et al. 2003; WHO 2004, 2008a,b, Vallely et al. 2007). In addition, the substantial reduction in the risk of LBW observed in Mikalayi and Kisangani, where SP resistance was 2% and 22%, respectively, is in line with the conclusions of a recent review of randomised trials reporting that with SP resistance up to 26% (no study done in places with higher SP resistance was found) the two-dose regimen of IPTp-SP provides substantial benefit, though more frequent dosing is required in HIV-positive pregnant women (ter Kuile et al. 2007). Similarly, another review on published and unpublished studies relating SP treatment efficacy in children and pregnant women with uncomplicated malaria and IPTp-SP noticed the lack of information in regions where SP resistance exceeds 50% (WHO 2008a,b). Therefore, the results reported in this study contribute to fill the knowledge gap as SP resistance in Rutshuru was around 60% and two IPTp-SP doses did not have a clear benefit on the birth weight as in the other two sites. However, the limitations inherent to this type of study, that is using data collected through the routine health information system, and the small number of sites should be considered.

The quality of data used may be questioned as they were not collected to investigate a specific research question, but rather to monitor the implementation of the IPTp-SP. Moreover, the women included in the study represent a selected group as they delivered in the health facilities. Observations in this group may not necessarily apply to women who delivered at home. Nevertheless, the fact that other known risk factors such as low BMI or prematurity were found independently associated with LBW in at least one of the sites is reassuring and may indicate that the dataset is of reasonable quality.

The three sites also represent areas of different endemicity, with Rutshuru, the site where two doses of IPTp-SP did not have any impact, being probably the one with the lowest intensity of transmission (Ministère de la Santé 2007; Taylor et al. 2011). Therefore, differences could be due to the lower malaria burden in Rutshuru. However, the little information available from this region indicates that this is unlikely. Prevalence of malaria infection was 17.4% in pregnant women attending the maternity hospital of Rutshuru, an area with unstable malaria transmission (Meuris et al. 1993) and 21% among delivering mothers in Kinshasa maternity hospitals, in an area of stable transmission (Lukuka et al. 2006).

It would have also been interesting to have other facilities in areas with high SP resistance. Data on SP efficacy were collected between 2002 and 2004; those on birth weight and IPTp-SP doses in 2007 – a gap of several years. The national policy on treatment changed in 2005, from SP to amodiaquine-artesunate, which may have had an impact on the prevalence of SP-resistant malaria parasites. This is probably unlikely as often the period between the decision of changing the national antimalarial drug policy and its implementation can be as long as 2–3 years (WHO 2006) and the time necessary to observe a change in the drug-resistance pattern may be even longer (Mita et al. 2003).

In conclusion, IPTp-SP seems to remain an effective strategy in areas where SP treatment failure in children with uncomplicated malaria is below 30% (34), while the effect seemed to be much lower where SP resistance was as high as 60%. The threshold value of SP resistance at which IPTp-SP fails to have a significant impact on birth weight and LBW is unknown. Considering that no alternative is currently available, additional studies on the efficacy of IPTp-SP in areas of high resistance such as Rutshuru are needed so that the threshold at which this intervention fails to provide any benefit is determined with some precision.

Acknowledgements

  1. Top of page
  2. Abstract
  3. Introduction
  4. Methods
  5. Results
  6. Discussion
  7. Acknowledgements
  8. References

We thank the Belgian Technical Cooperation for financial support.

References

  1. Top of page
  2. Abstract
  3. Introduction
  4. Methods
  5. Results
  6. Discussion
  7. Acknowledgements
  8. References
  • Alker AP, Kazadi WM, Kutelemeni AK, Bloland PB, Tshefu AK & Meshnick SR (2008) dhfr and dhps genotype and sulfadoxine-pyrimethamine treatment failure in children with falciparum malaria in the Democratic Republic of Congo. Tropical Medicine and International Health 13, 13841391.
  • Brabin BJ (1983) An analysis of malaria in pregnancy in Africa. Bulletin of The World Health Organisation 61, 10051016.
  • Brabin BJ, Agbaje SO, Ahmed Y & Briggs ND (1999) A birthweight nomogram for Africa, as a malaria-control indicator. Annals of Tropical Medicine and Parasitolology 93 (Suppl. 1), S43S57. [Abstract].
  • Breslow NE & Day NE (1987) Statistical Methods in Cancer Research; volume II: The Design and Analysis of Cohort Studies. Internation Agency for Research on Cancer (IARC Scientific publications N°82), Lyon.
  • Briand V, Cottrell G, Massougbodji A & Cot M (2007) Intermittent preventive treatment for the prevention of malaria during pregnancy in high transmission areas. Malaria Journal 6, 160. doi: 10.1186/1475-2875-6-160.
  • Desai M, ter Kuile FO, Nosten F et al. (2007) Epidemiology and burden of malaria in pregnancy. Lancet Infectious Diseases 7, 93104.
  • Greenwood BM, Bojang K, Whitty CM & Targett GAT (2005) Malaria. Lancet 365, 14871498.
  • Hosmer DW & Lesmeshow S (2000) Applied Logistic Regression, 2nd edn. Wiley-Interscience Publication, New York.
  • Kazadi WM, Vong S, Makina BN et al. (2003) Assessing the efficacy of chloroquine and sulfadoxine-pyrimethamine for treatment of uncomplicated Plasmodium falciparum malaria in the Democratic Republic of Congo. Tropical Medicine and International Health 8, 868875.
  • ter Kuile FO, van Eijk AM & Filler SJ (2007) Effect of the sulfadoxine-pyrimethamine resistance on the efficacy of intermittent preventive therapy for malaria control during pregnancy. A systematic review. Journal of American Medical Association 297, 26032616.
  • Lagerberg RE (2008) Malaria in pregnancy: a literature review. Journal of Midwifery & Women’s Health 53, 209215.
  • Lukuka KA, Fumie OS, Mulumbu MR et al. (2006) Pévalence du paludisme à l’accouchement dans quatre maternités de la ville de Kinshasa, République Démocratique du Congo. Bulletin de la Societe de Pathologie Exotique 99, 12.
  • McCormick MC (1985) The contribution of low birth weight to infant mortality and childhood morbidity. New England Journal of Medicine 312, 8290 [Abstract].
  • Menendez C, Romagosa C, Ismail MR et al. (2008) An Autopsy Study of Maternal Mortality in Mozambique: the contribution of infectious diseases. PLoS Medicine 5, e44. doi: 10.1371/journal.pmed.0050044.
  • Menéndez C, D’Alessandro U & ter Kuile FO (2007) Reducing the burden of malaria in pregnancy by preventive strategies. Lancet Infectious Diseases 7, 126135.
  • Meuris S, Piko BB, Eerens P, Vanbellinghen AM, Dramaix M & Hennart P (1993) Gestational malaria: assessment of its consequences on fetal growth. American Journal of Tropical Medicine and Hygiene 48, 603609.
  • Ministère de la Santé, République Démocratique du Congo, Programme Nationale de Lutte contre le Paludisme (2007) « Faire Reculer le Paludisme » Plan stratégique 2007–2011. République Démocratique du Congo, Kinshasa.
  • Ministère du Plan et Macro International (2008) Enquête Démographique et de Santé, République Démocratique du Congo 2007. Ministère du Plan et Macro International, Calverton, MD.
  • Mita T, Kaneko A, Lum J et al. (2003) Recovery of chloroquine sensitivity and low prevalence of the plasmodium falciparum chloroquine resistance transporter gene mutation K76t following the discontinuance of chloroquine use in Malawi. American Journal of Tropical Medicine and Hygiene 68, 413415.
  • Mutabingwa KT, Bolla CM, Li J-L et al. (2005) Maternal malaria and gravidity interact to modify infant susceptibility to malaria. PLoS Medicine 2, e407, 12601268.
  • Newman RD, Parise ME, Slutsker L, Nahlen B & Steketee RW (2003) Safety, efficacy and determinants of effectiveness of antimalarial drugs during pregnancy: implications for prevention programmes in Plasmodium falciparum-endemic sub-Saharan Africa. Tropical Medicine and International Health 8, 488506.
  • Odio W (2005) Rapport de la revue de résultats des études de l’évaluation de l’efficacité thérapeutique des antipaludiques en République Démocratique du Congo de mars 1996 a juin 2004. Programme National de lutte contre le paludisme, Kinshasa.
  • Rogerson SJ, Hviid L, Duffy PE, Leke RFG & Taylor DW (2007) Malaria in pregnancy: pathogenesis and immunity. Lancet Infectious Diseases 7, 105117.
  • Sirima BS, Cotte HA, Konaté A et al. (2006) Malaria prevention during pregnancy: assessing the disease burden one year after implementing a program of intermittent preventive treatment in Koupéla district, Burkina Faso. American Journal of Tropical Medicine and Hygiene, 75, 205211.
  • Steketee RW (2003) Pregnancy, nutrition and parasitic diseases. The Journal of Nutrition 133 (Suppl.), 16611667.
  • Steketee RW, Nahlen BL, Parise ME & Menendez E (2001) The burden of malaria in pregnancy in malaria-endemic areas. American Journal of Tropical Medicine and Hygiene 64 (Suppl. 1–2), 2835.
  • Taylor SM, Messina JP, Hand CC et al. (2011) Molecular malaria epidemiology: mapping and burden estimates for the Democratic Republic of the Congo, 2007. PLoS ONE 6, e16420. doi: 10.1371/journal.pone.0016420.
  • Vallely A, Vallely L, Changalucha J, Greenwood B & Chandramohan D (2007) Intermittent preventive treatment for malaria in pregnancy in Africa: what’s new, what’s needed? Malaria Journal 6, 16 (http://www.malariajournal.com/content/6/1/16).
  • Van Geertruyden JP, Thomas F, Erhart A & D’Alessandro U (2004) The contribution of malaria in pregnancy to perinatal mortality. American Journal of Tropical Medicine and Hygiene 71 (Suppl. 2), 3540.
  • White NJ (2005) Intermittent presumptive treatment for malaria. PLoS Medicine 2, e3. doi: 10.1371/journal.pmed.0020003.
  • WHO & UNICEF (2003) Antenatal Care in Developing Countries: Promises, Achievements and Missed Opportunities: An Analysis of Trends, Levels and Differentials, 1990–2001. World Health Organization, Geneva.
  • World Health Organization (2004) A Strategic Framework for Malaria Prevention and Control During Pregnancy in the Africa Region. WHO Regional offices for Africa, Brazzaville.
  • World Health Organization (2005a) The World Health Report 2005, Make Every Mother and Child Count. WHO, Geneva, 68.
  • World Health Organization (2005b) Recommendations on the Use of Sulfadoxine-Pirymethamine (SP) for Intermittent Preventive Treatment During Pregnancy (IPT) in Areas of Moderate to High Resistance to SP in Africa Region. WHO, Regional office for Africa, Brazzaville. Available from: http//:afro.who.int/malaria/publications/who_sp_ statment.pdf. Accessed on October 17th 2008.
  • World Health Organization (2006) The Africa Malaria Report 2006. WHO Regional offices for Africa and Eastern Mediteranean.
  • World Health Organization (2008a) Technical Expert Group Meeting on Intermittent Preventive Treatment in Pregnancy (IPTp). WHO headquarter, Geneva.
  • World Health Organization (2008b) World Malaria Report 2008. WHO, Genève.